Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, HMA, and GPBMC Infusion for Intermediate/High-Risk MDS
NCT07238686Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, peripheral blood mononuclear cells in myelodysplastic syndrome (MDS), sponsored by The Fifth Medical Center of the PLA General Hospital. Started Jun 2025; status: recruiting.
02
Drugs
venetoclaxperipheral blood mononuclear cells
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07238686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238686.